The Indianapolis Foundation Library Partners

In 1989 an anonymous bequest of nearly $15 million was made to The Indianapolis Foundation, creating the Library Fund, which would be used to support Marion County libraries. This group, which would come to be called The Indianapolis Foundation Library Partners, was made up of the Indianapolis Marion County Public Library (IMCPL); the libraries of all of the public, private, and parochial high schools in Marion County; and the libraries of Indiana University Purdue University Indianapolis (IUPUI), Marian College, and the University of Indianapolis. The donor stipulated that that The Indianapolis Foundation “shall give preference to projects which cannot be met by the operating budgets of the recipient institutions.” Further, the donor expressed a hope that, “in exercising its discretion, the Foundation will emphasize provision of books and other library materials rather than the employment of personnel and the construction of buildings.” Thus the proceeds of the Library Fund were to be used for new, innovative, and collaborative projects. Core library operation expenses and building projects were excluded. This remarkable gift created a resource, now valued at approximately$25 million and producing approximately $1.25 million a year, that is truly unique. Since its beginning in 1989, the Library Fund has made over$16 million in grants to Marion County libraries. This resource in turn fostered a collaborative environment among the libraries and librarians in Marion County that is also unique. In this article we describe the history of The Indianapolis Foundation Library Partners, its current programs, and its growth over the years

The Vehicle, 1966, Vol. 8

Vol. 8 Table of Contents CommentaryBill Moser & Avis Eaglestonpage 3 The Vengeance of the DeadStephen W. Gibbspage 5 Ode To A MeadowKathleen McCormackpage 12 Row OnDavid Helmpage 13 Sonnet 63R.L. Hudsonpage 14 UntitledKathleen McCormackpage 14 The Pure GoldDavid Helmpage 15 CommunionDavid Helmpage 15 PreludeMichael Baldwinpage 15 The AlbatrossKaren Cooleypage 16 The Albatross (photo)DeWittpage 17 Ruff and the VaseDavid Helmpage 18 LaBelleKathleen McCormackpage 19 Not Quite SoR.L. Hudsonpage 20 Feeling (no number)David Reifpage 21 Song at DuskDavid Helmpage 21 Arcadia RuminationsR.L. Hudsonpage 22 The BarWayne Johnsonpage 25 HelloWilliam Framepage 26 The ProcessJerry DeWittpage 27 The KillingAdrian Beardpage 30 The Amusement Park GameStephen W. Gibbspage 38 DamnMel Tylerpage 40 PainWilliam Framepage 40 UntitledSusan Champlinpage 41 Portrait of A Scholar As A Young ManStephen W. Gibbspage 42 The TimesW.D.Mpage 46 ParadoxW.D.M.page 46 MankindDavid Helmpage 47https://thekeep.eiu.edu/vehicle/1014/thumbnail.jp

The Vehicle, 1966, Vol. 8

Vol. 8 Table of Contents CommentaryBill Moser & Avis Eaglestonpage 3 The Vengeance of the DeadStephen W. Gibbspage 5 Ode To A MeadowKathleen McCormackpage 12 Row OnDavid Helmpage 13 Sonnet 63R.L. Hudsonpage 14 UntitledKathleen McCormackpage 14 The Pure GoldDavid Helmpage 15 CommunionDavid Helmpage 15 PreludeMichael Baldwinpage 15 The AlbatrossKaren Cooleypage 16 The Albatross (photo)DeWittpage 17 Ruff and the VaseDavid Helmpage 18 LaBelleKathleen McCormackpage 19 Not Quite SoR.L. Hudsonpage 20 Feeling (no number)David Reifpage 21 Song at DuskDavid Helmpage 21 Arcadia RuminationsR.L. Hudsonpage 22 The BarWayne Johnsonpage 25 HelloWilliam Framepage 26 The ProcessJerry DeWittpage 27 The KillingAdrian Beardpage 30 The Amusement Park GameStephen W. Gibbspage 38 DamnMel Tylerpage 40 PainWilliam Framepage 40 UntitledSusan Champlinpage 41 Portrait of A Scholar As A Young ManStephen W. Gibbspage 42 The TimesW.D.Mpage 46 ParadoxW.D.M.page 46 MankindDavid Helmpage 47https://thekeep.eiu.edu/vehicle/1014/thumbnail.jp

Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1

AbstractOne hundred patients of median age 34 years (range, 14-53) received bone marrow transplants from unrelated donors serologically matched for human leukocyte antigen HLA-A, HLA-B, and HLA-DR using tacrolimus and minimethotrexate for prevention of acute graft-versus-host disease (GVHD). Sixty-eight patient-donor pairs had allelic matches at HLA-DRB1 and HLA-DQB1, 20 pairs had a single mismatch at HLA-DRB1 or HLA-DQB1, and 12 were mismatched at both HLA-DRB1 and HLA-DQB1. Minimum follow-up time was 6 months. Grades 2 to 4 GVHD occurred in 43% of patients with matched donors, 69% with single allele-mismatched donors, and 71% with double allele-mismatched donors; grades 3 to 4 GVHD occurred in 22%, 43%, and 64%, respectively. On multivariate analysis, the relative risk of grades 2 to 4 GVHD was 2.2 (95% CI, 1.1-4.5; P = .03) with a single allele mismatch and 2.7 (95% CI, 1.2-6.0; P = .02) with a double allele mismatch. The relative risks of grades 3 to 4 GVHD were 3.0 (95% CI, 1.2-7.6; P = .02) and 5.0 (95% CI, 1.9-12.6; P = .001), respectively. Day 100 treatment-related mortality was also adversely affected by allelic mismatching, occurring in 21% of those with matched donors, 50% with single allele-mismatched donors, and 42% with double allele-mismatched donors (P = .02), but overall survival at day 180 did not differ significantly among the 3 groups. Tacrolimus does not abrogate the adverse impact of allele mismatching at HLA-DRB1 and HLA-DQB1 on the risk of moderate-to-severe acute GVHD.Biol Blood Marrow Transplant 2000;6(2A):190-7

Clinical Relevance of Myc/BCL2 Expression and Cell of Origin in Patients With Diffuse Large B-Cell Lymphoma Treated With Autologous Transplant

Dual expression of MYC and BCL2 proteins (double-expressor lymphoma [DEL]) as well as cell of origin (COO) are important prognostic factors in patients with diffuse large B-cell lymphoma (DLBCL) after conventional chemotherapy. We studied the prognostic impact of DEL and COO in patients with relapsed DLBCL treated with autologous stem cell transplant (ASCT). Three-hundred and three patients with stored tissue samples were identified. Classification was successful in 267 patients: 161 (60%) were DEL/non-double hit (DHL), 98 (37%) were non-DEL/non-DHL, and 8 (3%) were DEL/DHL. Compared to non-DEL/non-DHL, DEL/DHL had worse overall survival while DEL/non-DHL did not significantly differ in overall survival. On multivariable analysis, DEL/DHL, age \u3e60 years, and \u3e2 prior therapies, but not COO, were important prognostic factors for overall survival. When we explored the interaction of COO and BCL2 expression, patients with germinal center B-cell (GCB)/BCL2 (+) had inferior progression-free survival (PFS) compared to GCB/BCL2 (-) patients (HR, 4.97; P = 0.027). We conclude that the DEL/non-DHL and non-DEL/non-DHL subtypes of DLBCL have similar survival after ASCT. The negative impact of GCB/BCL2 (+) on PFS warrants future trials targeting BCL2 after ASCT. The inferior outcomes in DEL/DHL need to be verified in a larger number of patients

Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment after Hematopoietic Cell Transplantation

Pulmonary chronic graft-versus-host-disease (cGVHD), or bronchiolitis obliterans syndrome (BOS), is a highly morbid complication of hematopoietic cell transplantation (HCT). The clinical significance of a single instance of pulmonary decline not meeting the criteria for BOS is unclear. We conducted a retrospective analysis in a cohort of patients who had an initial post-HCT decline in the absolute value of forced expiratory volume in 1 second (FEV1) of ≥10% or mid-expiratory flow rate of ≥25% but not meeting the criteria for BOS (pre-BOS). We examined the impact of clinical variables in patients with pre-BOS on the risk for subsequent BOS. Pre-BOS developed in 1325 of 3170 patients (42%), of whom 72 (5%) later developed BOS. Eighty-four patients developed BOS without detection of pre-BOS by routine screening. Among patients with pre-BOS, after adjusting for other significant variables, airflow obstruction (hazard ratio [HR], 2.0; 95% confidence interval [CI], 1.1 to 3.7; P = .02), percent-predicted FEV1 on decline (HR, .98; 95% CI, .97 to 1.0; P = .02), active cGVHD (HR, 7.7; 95% CI, 3.1 to 19.3; P \u3c .001), peripheral blood stem cell source (HR, 3.8; 95% CI, 1.7 to 8.6; P = .001), and myeloablative conditioning (HR, 2.0; 95% CI, 1.1 to 3.5; P = .02) were associated with subsequent BOS. The absence of airflow obstruction and cGVHD had a negative predictive value of 100% at 6 months for subsequent BOS, but the positive predictive value of both factors was low (cGVHD, 3%; any obstruction, 4%; combined, 6%). Several clinical factors at the time of pre-BOS, particularly active cGVHD and airflow obstruction, increase the risk for subsequent BOS. These factors merit consideration to be included in screening practices to improve the detection of BOS, with the caveat that the predictive utility of these factors is limited by the overall low incidence of BOS among patients with pre-BOS

HLA Factors versus Non-HLA Factors for Haploidentical Donor Selection

When multiple haploidentical donors are available for transplantation, those of younger generations are generally selected over those of older generations. However, it is unclear who is the optimal donor when selecting candidates from within a generation, such as father versus mother, son versus daughter, or brother versus sister. Although traditionally male donors are favored over female donors, particularly for male recipients, and significant associations of individual HLA mis(matches) on outcomes are being increasingly recognized, the hierarchy of factors for donor selection is indeterminate. To assess whether HLA factors take precedence over non-HLA factors and to isolate the influence of specific characteristics on outcomes, we analyzed 412 patients stratified by donor relationship: child donor (son [n = 202] versus daughter [n = 96]), parent (father [n = 28] versus mother [n = 29]), and sibling (noninherited maternal [NIMA; n = 29] versus paternal [NIPA; n = 28] mismatched). Among siblings, NIMA mismatch was associated with a lower risk of acute graft-versus-host disease (aGVHD); B-leader mismatch was associated with high nonrelapse mortality (NRM), poor progression-free survival, and a trend toward poor overall survival (OS), whereas A-mismatch was associated with lower aGVHD. Among parent donors, the relationship did not impact any outcome; B-leader mismatch was associated with higher NRM and a trend toward poor OS, whereas A-mismatch was associated with lower NRM and improved progression-free survival and OS. Among child donors, no individual HLA mismatch was predictive of any outcome, and daughter donors were not associated with any adverse outcomes in multivariate analyses. Our data suggest that certain HLA factors may be more significant in some cases and should be given priority over simply selecting a donor based on relationship/sex

Loss of Metabolic Fitness Drives Tumor Resistance After CAR-NK Cell Therapy and Can Be Overcome by Cytokine Engineering

Chimeric antigen receptor (CAR) engineering of natural killer (NK) cells is promising, with early-phase clinical studies showing encouraging responses. However, the transcriptional signatures that control the fate of CAR-NK cells after infusion and factors that influence tumor control remain poorly understood. We performed single-cell RNA sequencing and mass cytometry to study the heterogeneity of CAR-NK cells and their in vivo evolution after adoptive transfer, from the phase of tumor control to relapse. Using a preclinical model of noncurative lymphoma and samples from a responder and a nonresponder patient treated with CAR19/IL-15 NK cells, we observed the emergence of NK cell clusters with distinct patterns of activation, function, and metabolic signature associated with different phases of in vivo evolution and tumor control. Interaction with the highly metabolically active tumor resulted in loss of metabolic fitness in NK cells that could be partly overcome by incorporation of IL-15 in the CAR construct